Ondine Biomedical Share Discussion Threads

[jailbird] 17/1/2025 12:56

I am more interested in the market cap Revenues , profits , and plus the value of the patented technology Over £250m spent on this already It will become a takeover target at some point and with BoD holding 40% , it will not go cheaply Huge Potential revues after FDA approval

[someuwin] 16/1/2025 12:16

Bowl forming in the chart. Very bullish.

Phase 3 trial results expected in Autumn this year.

Expect buying to build up ahead of trial results.

Singer has a 12m target price of 65p.

All good reasond to be buying now imo.

[jailbird] 15/1/2025 21:53

comment on other chat BB

Maybe the results of the UK health economics study (hopefully with a very positive outcome) will be available soon.

The other possibility that occurs to me is the impact Mölnlycke® may be having:

"Mölnlycke® will incorporate Steriwave as a key product in its infection control portfolio, enhancing its product offerings with a focus on preventing HAIs and reducing AMR. Distribution will commence in the UK in Q4 2024, followed by expansion into the EU and Middle East regions in 2025, leveraging Mölnlycke's extensive market presence to ultimately broaden the impact of this innovative technology on a global scale. Mölnlycke will spearhead sales and marketing efforts across the UK, EU, and Middle East."

[bamboo2] 15/1/2025 18:58

Good to see the lift in volume to over 1.2m

[jailbird] 15/1/2025 16:06

lol....just joined with a new alias I see , is that more than one you have now ?

[darmz] 15/1/2025 16:02

Nothings leaked

[jailbird] 15/1/2025 15:04

Boom Just logged in , something leaked I think

[jailbird] 15/1/2025 13:25

Buyers of late , finally ticked up again today Good to see the potential by a few is now being noticed

[jailbird] 07/1/2025 10:35

Looks to me we have a 50k buying up when price falls to 9p.

[jailbird] 03/1/2025 15:15

Bamboo,

Did you see the numbers from the Edison note:

While we note that it is a complex process to quantify this, the number of annual discharges from the c 6,000 hospitals in the US is estimated to be approximately 35m.

Thats $2.6B annually @$75 if all 35m were on disinfection, so excluding ICU pricing of $275,
if OBI just take a conservative 10% of the 35m in the just US hospitals, that £260m!!
Thats excluding the Rest of the World


Numbers are huge

[bamboo2] 30/12/2024 08:52

4,999 to go!

Good to see this get going before year end.

============================

Ondine recruits first patient for US Phase 3 trial



Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company, has enrolled and treated the first patient in the Light-Activated Antimicrobial Therapy to Prevent Surgical Site Infections ('LANTERN') Phase 3 clinical trial. The trial, involving approximately 5,000 patients in 14 hospitals, is evaluating Ondine's non-antibiotic nasal photodisinfection technology, branded as Steriwave® outside the US. The first patient was enrolled at Centennial Medical Center in Nashville, Tennessee, on Friday December 27th, 2024.



The Phase 3 trial is being conducted in collaboration with HCA Healthcare, a leading healthcare provider in the United States. This group-randomized crossover study will enroll approximately 5,000 surgical patients undergoing cardiac, orthopaedic, vascular, neurosurgical or radical mastectomy procedures. The study will compare standard infection prevention practices with, and without, Ondine's nasal photodisinfection technology in order to reduce the incidence of surgical site infections. The final patient is expected to enroll in mid-2025, and preliminary trial results are projected for release in Autumn 2025.



Ondine Biomedical's CEO Carolyn Cross said:



"Our US Phase 3 trial initiation is an exciting milestone towards making photodisinfection technology available to healthcare professionals who want to rapidly eliminate a broad spectrum of infection-causing pathogens without fuelling drug resistance or relying on patient compliance as is the case with topical antibiotics."



Ondine's nasal photodisinfection is a 5-minute, non-invasive procedure that rapidly decolonizes the nose of infection-causing pathogens without the use of antibiotics. This innovative approach avoids contributing to antimicrobial resistance (AMR). The process involves applying a proprietary photosensitive agent to each nostril with a nasal swab, followed by illumination with a specific wavelength of red light. The light activates the agent, producing an oxidative burst that destroys bacteria, viruses and fungi in a single treatment.



Nasal decolonization is recommended in the 2016 WHO Global guidelines for the prevention of surgical site infections,[1] and the Society for Healthcare Epidemiology of America (SHEA) guidelines, published in May 2023, recommend nasal decolonization for major surgical procedures.[2]

[jailbird] 30/12/2024 08:03

FDA trials have started with first patient
Looking forward to 2025
Happy new year all

[jailbird] 27/12/2024 08:50

Just gonna put this here as I lost this hxxps://ondinebio.com/wp-content/uploads/2024/09/Ondine-Biomedical-2024-Mid-year-Management-Update.pdfFrom Edison notehttps://www.edisongroup.com/research/proprietary-platform-testing-standard-of-care/32309/Steriwave into the standard of care for surgical procedures, a long-term vision for Ondine is to see Steriwave included as a standard protocol for all in-patients across the US. While we note that it is a complex process to quantify this, the number of annual discharges from the c 6,000 hospitals in the US is estimated to be approximately 35m. More specifically, the global infection control market was valued at US$50bn in 2022 by Markets and Markets. If Ondine is successful in capturing even a small portion of the infection control market, this could result in potentially significant future revenue.

[purple11] 20/12/2024 21:13

yeah just go away zico

[premium beeks] 20/12/2024 21:10

Another board ruined by you eh?

[premium beeks] 20/12/2024 20:07

Like I say, absolute nobhead.

[purple11] 20/12/2024 09:25

I expect this to be capped around 100-130million once theyve got FDA approval.


M@G fund didint listen to the utter rubbish posted by ADFVN loon zico and now hold over 10% of the company.That is a massive sign of confidence.

[z1co] 20/12/2024 09:05

beeks you idiot my comments above have nothing to do with purple

Grow up old man!!!

The cash burn is far too high ,how many placings have they done over the last year.

Too many and they are still losing $15m to $16m a year.

It will take them years to grow revenues in excess of $16m and until then the company will continue to lose money.

More placings in 2025

Hope this helps you old man

[premium beeks] 20/12/2024 08:47

Also remember that, whilst Z1co is correct, he's only commenting again here due to his spat with Purple11.You would think those two clowns would grow up. Obviously not.

[jailbird] 20/12/2024 08:38

PBIf you take into account these figures , note we know alot if the money is going towards FDA approval This small amount will take cash to Q1 2027 , so that tells you their costs have come down a lot since it will be starting commercialisation phase In the event that the Company concludes the ongoing discussions with a major U.S. healthcare group regarding a potential investment of up to US$4 million (?3.1 million) the Company's expected cash runway would be into Q1 2027!Cash requirements if needed later will be raised at much higher prices

[premium beeks] 20/12/2024 07:59

The company has a proven product - used by my daughter in Pinderfields in fact. However the facts don't lie - Z1co is right that money will be required.Sat on my hands for the moment. However could have a run on any P3 news.Hard one to pin down short term.

[jailbird] 20/12/2024 07:20

Zico I am well aware of the market cap , that's why i am not expecting this to fly up into silly prices . I will keep an eye on R&D costs too. Remember alot of shares are in sticky hands now The patent technology has serious value , having spent £250m developing it Look forward not backwards now , and I will follow the market movements Have a look at previous posts on potential revenues , they are huge globally

[z1co] 19/12/2024 23:28

Capped at £32m and revenue for 6 months to 30th June was only $0.9m , will lose $15.5m again in 2024.

Far too expensive ,remember they have generate revenue in excess of $15.5m to stop losing money and until then expect more placings.